Modulating the BI-1(TMBIM6)/AKT Signaling Pathway by Licochalcone D Treatment Inhibits Human Melanoma Cell Growth

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Skin cancer, particularly melanoma, presents a growing global health challenge.
• Phytochemicals offer potential therapeutic strategies due to their low cytotoxicity and cost-effectiveness.
• Licochalcone D (LicoD) is a phytochemical with potential anticancer properties.

Purpose of the Study:

• To investigate the anti-melanoma effects of Licochalcone D (LicoD).
• To elucidate the underlying molecular mechanisms of LicoD's action in human melanoma cells.
• To evaluate LicoD's efficacy in a preclinical skin inflammation model.

Main Methods:

• Cell viability (MTT) and soft agar assays were used to assess melanoma cell proliferation.
• Flow cytometry and Western blotting were employed to analyze cell cycle, apoptosis, and protein expression.
• MS/MS-based proteomic analysis identified key molecular targets.
• A TPA-induced mouse model was used to evaluate in vivo effects.

Main Results:

• LicoD dose-dependently inhibited melanoma cell growth, induced G2/M cell cycle arrest, and promoted apoptosis.
• LicoD suppressed the expression of Bax inhibitor-1 (BI-1/TMBIM6), an upstream regulator of the AKT signaling pathway.
• Knockdown of BI-1 confirmed its critical role in melanoma proliferation, and LicoD's effects were partially dependent on BI-1.
• Topical LicoD treatment reduced skin inflammation markers in vivo.

Conclusions:

• Licochalcone D exhibits significant anti-melanoma activity through the down-regulation of the BI-1/AKT signaling pathway.
• BI-1 plays a crucial role in melanoma cell proliferation and anchorage-independent growth.
• LicoD demonstrates potential as a therapeutic agent for skin cancer prevention and treatment.